Fate Therapeutics - FATE Stock Forecast, Price & News

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Analysts Set New Price Targets

Several analysts have issued reports on FATE shares. Oppenheimer cut their target price on shares of Fate Therapeutics from $135.00 to $90.00 in a research note on Thursday, August 4th. Robert W. Baird initiated coverage on shares of Fate Therapeutics in a research note on Thursday, June 2nd. They issued a "neutral" rating and a $28.00 price target on the stock. Piper Sandler dropped their price target on shares of Fate Therapeutics from $113.00 to $71.00 and set an "overweight" rating on the stock in a research note on Monday, May 23rd. Needham & Company LLC initiated coverage on shares of Fate Therapeutics in a research note on Thursday, July 28th. They issued a "hold" rating on the stock. Finally, BMO Capital Markets raised shares of Fate Therapeutics from a "market perform" rating to an "outperform" rating and dropped their price target for the stock from $50.00 to $47.00 in a research note on Monday, July 11th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, Fate Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $75.42.

Fate Therapeutics Stock Up 6.6 %

FATE Stock traded up $2.24 during mid-day trading on Monday, reaching $36.06. 1,623,514 shares of the stock traded hands, compared to its average volume of 1,473,188. Fate Therapeutics has a 52 week low of $17.10 and a 52 week high of $91.90. The business has a 50-day moving average of $27.90 and a two-hundred day moving average of $31.18. The firm has a market capitalization of $3.50 billion, a PE ratio of -13.10 and a beta of 1.62.

Insider Buying and Selling at Fate Therapeutics

In other Fate Therapeutics news, insider Mark Plavsic sold 3,719 shares of the company's stock in a transaction dated Tuesday, July 5th. The shares were sold at an average price of $24.61, for a total transaction of $91,524.59. Following the completion of the sale, the insider now directly owns 127,123 shares in the company, valued at $3,128,497.03. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, insider Mark Plavsic sold 3,719 shares of the stock in a transaction dated Tuesday, July 5th. The shares were sold at an average price of $24.61, for a total value of $91,524.59. Following the completion of the sale, the insider now owns 127,123 shares in the company, valued at $3,128,497.03. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO J Scott Wolchko sold 30,000 shares of the stock in a transaction dated Thursday, July 21st. The shares were sold at an average price of $32.88, for a total transaction of $986,400.00. Following the completion of the sale, the chief executive officer now owns 431,546 shares of the company's stock, valued at approximately $14,189,232.48. The disclosure for this sale can be found here. Insiders sold 53,082 shares of company stock worth $1,646,106 over the last ninety days. Company insiders own 17.34% of the company's stock.